The Molecular Oncology group of the Universidad Francisco de Vitoria-Hospital 12 de Octubre (UFV-H12O) is interested in exploring the pathophysiology of pancreatic ductal adenocarcinoma (PDAC) and the search for new therapeutic targets to improve the treatment of this type of tumor. To this end, we have focused on the study of transcriptional programs and epigenetic regulation of biological processes related to the development and progression of this type of tumor, such as cell proliferation, metabolic reprogramming and modification of the tumor microenvironment. Specifically, our group has focused on the study of the transcription factor c-MYC -amplified and/or overexpressed in ADP- and chromatin remodelers necessary for its transcriptional activity.
Neoantigens and Cancer Vaccines – Núria de la Iglesia
The Neoantigens and Cancer Vaccines group (NeoVaCan) is part of the IrsiCaixa Institute for Research on Immunopathologies, a center dedicated to the study of diseasesrelated to the immune system, ranging from viral infections, such as HIV or SARS-CoV-2, to cancer. Our...

